The Fuzzy Factor: Striving to Protect Patient Privacy in Big Data Sets

A major objective of former Vice President Joe Biden’s National Cancer Moonshot Initiative is breaking down silos and sharing cancer patients’ data across centers. This path is critical to bringing new dimensions to understanding the molecular biology of cancer, leading to the rapid identification of new therapeutic targets and accelerated development of molecularly informed cancer therapeutics.

Read More

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More

Catching Childhood Cancers Early: Insights Into the AACR Childhood Cancer Predisposition Workshop

There is perhaps nothing more painful for parents than receiving a cancer diagnosis for their child. Childhood cancers are generally rare, and in the United States, the death rates have …

Read More

Advancing Translational Cancer Medicine in Latin America

In recent years, the American Association for Cancer Research (AACR) has expanded its efforts to catalyze advances in cancer research globally and support its members residing in 107 countries in addition to the United States. One important initiative this year was the landmark conference held May 4-6, in São Paulo, Brazil—the AACR International Conference on Translational Cancer Medicine.

Read More

AACR Annual Meeting 2017: Challenging the Dogma of Treating IDH-mutant Cancers With IDH Inhibitors

Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to that of BRCA-mutant tumors and are, therefore, more likely to respond better to PARP inhibitors than to IDH inhibitors.

Read More